@FierceBiotech: CytomX 'probody' kills pancreatic cancer cells, leaves healthy tissue intact. Story from FierceBiotech Research | Follow @FierceBiotech
@JohnCFierce: UPDATED: FDA overrides Zohydro panel, approves pure hydrocodone pain med. Story | Follow @JohnCFierce
@DamianFierce: ICYMI: Aerie prices $67M IPO and becomes 40th biotech to go public this year. Story | Follow @DamianFierce
@EmilyMFierce: GMOs Versus Overuse Of Antibiotics: Which Is The Greater Evil? More from Forbes | Follow @EmilyMFierce
> Citi analysts say that Merck ($MRK) is preparing to take its failed CCR5 HIV drug vicriviroc--which is designed to block the AIDS virus from penetrating cells--into the clinic as a combo drug with its closely-watched PD-1 immunotherapy MK-3475. And Pfizer ($PFE) and Bristol-Myers Squibb ($BMY) could pursue the same combination strategy. Speculation about a combination has been growing following promising animal studies for vicriviroc. The therapy was abandoned in 2010 after it failed two Phase III studies. Report
> Lexington, MA-based Synta Pharmaceuticals ($SNTA) saw its share price plunge 22% Monday morning after it issued a "positive" update on its one-year results for the late stage lung cancer drug ganetespib. Some analysts found the data didn't measure up to competing therapies in the pipeline. Release
> Karyopharm has laid out its terms for an IPO. The biotech plans to sell 5.7 million shares at $14 to $16 each, raising up to $91 million. Story
@FierceMedDev: Abbott's MitraClip heart valve device gains FDA's long-awaited blessing. ICYMI Friday | Follow @FierceMedDev
@MarkHFierce: GE healthcare is aiming for a 2014 launch for its new Alzheimer's imaging agent. More from FierceDiagnostics | Follow @MarkHFierce
@MichaelGFierce: A blog post from the FDA late last week highlighted the agency's efforts to regulate nanotechnology. Blog | Follow @MichaelGFierce
> Boston Scientific bags CE mark for heart valve as market crowds. News
> Bill would clarify FDA oversight over mobile medical apps. Story
> Edwards joins Middle Peak financing to gain stake in mitral device race. More
Pharma News
@FiercePharma: Still trending on our website (in a big way): Teva profile as No. 1 on our Top 10 Generics Makers list. Profile | Follow @FiercePharma
@EricPFierce: What drugs are up for grabs by generic makers next year? Here's the FiercePharma list of 2014 patent losses. Report | Follow @EricPFierce
@CarlyHFierce: Biogen's Tecfidera drives rosy Q3 results, higher forecast. More | Follow @CarlyHFierce
> Suffering Dendreon puts itself on the block, Bloomberg says. Report
> Teva denies CEO weighing an exit over board's meddling. Story
> With Opsumit approved, analysts say Actelion primed for takeover. Article
CRO News
> InVentiv opens U.K. hub as EU demand climbs. More
> Dendreon picks CMO PharmaCell to make Provenge in Europe. Item
> Novum reaches into N. Dakota for clinical trials. Article
> SRI sets sights on CRO growth with Virginia expansion. Story
> Icon boosts outlook after 19% sales jump. Report
> CRO Atheris hooks up with Debiopharm for cancer R&D. More
Biotech IT News
> Medidata eyes Novartis' business after inking Alcon deal. More
> Broad Institute to offer sequencing services after receiving CLIA nod. Item
> VCs tap Amgen-acquired genomics database to power startup. Report
> Oxford Nanopore readying for user tests of handheld sequencing device. Story
> Amazon, Baylor and DNAnexus team up for huge sequencing project. Article